We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
- Authors
May, Taymaa; Bernardini, Marcus; Lheureux, Stephanie; Aben, Katja K.H.; Bandera, Elisa V.; Beckmann, Matthias W.; Benitez, Javier; Berchuck, Andrew; Bjørge, Line; Carney, Michael E.; Cramer, Daniel W.; deFazio, Anna; Dörk, Thilo; Eccles, Diana M.; Friedlander, Michael; García, María Jose; Goode, Ellen L.; Hein, Alexander; Høgdall, Claus K.; Jensen, Allan
- Abstract
Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan–Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.
- Subjects
OVERALL survival; SURVIVAL rate; MULTIVARIATE analysis; PROGRESSION-free survival; TREATMENT effectiveness
- Publication
Canadian Journal of Surgery, 2023, Vol 66, Issue 3, pE310
- ISSN
0008-428X
- Publication type
Article
- DOI
10.1503/cjs.017020